COPD Management: Azithromycin Based on Mucus Properties

We are studying whether prescribing azithromycin based on mucus rheology helps reduce COPD flare-ups compared to standard treatment. This trial aims to improve care for patients with chronic airway disease.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Azithromycin Dihydrate
Azithromycin Dihydrate is an antibiotic substance used to treat various bacterial infections, such as respiratory, ear, and skin infections.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Bordeaux
Explorations fonctionnelles respiratoires
Canéjan, France
Centre Hospitalier Universitaire De Montpellier
Maladies respiratoires, Pneumologie
Montpellier, France
Centre Hospitalier Universitaire De Toulouse
Pneumologie
Ramonville-Saint-Agne, France
Sponsor: Centre Hospitalier Universitaire De Montpellier
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.